RxDoctor Payments Data

James Twesten Otoole, MD

Addiction Medicine · Norton Shores, MINPI 1174599344

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.5% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Pfizer at 24.7% of the total.

$995in general payments, 2019–2025

Across 83 payments — averaging $11.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$246
  • Amarin Pharma, Inc.$162
  • Amgen$71
  • Supernus Pharmaceuticals, Inc.$53
  • Teva Pharmaceuticals USA, Inc.$51
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$44
  • plus $367 from 16 others

What the payments were for

  • Food & beverage$93093%
  • Education$657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$995 in reported general payments places this provider in the 75th percentile of 62 addiction medicine providers in Michigan.

See all addiction medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$9,704
Medicare patients
14
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl196$34,916
ZubsolvBuprenorphine Hcl/Naloxone Hcl15$9,218
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$6,530
Acamprosate Calcium29$2,761
Naltrexone Hcl73$2,672
Varenicline Tartrate16$2,361
Atorvastatin Calcium42$775
Disulfiram13$718
Bupropion Hcl SrBupropion Hcl26$305
Gabapentin25$302
Fluticasone Propionate12$265
Paroxetine Hcl11$256
Amlodipine Besylate28$220
Levothyroxine Sodium11$200
Bupropion XlBupropion Hcl12$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$31$6,53013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 62 addiction medicine providers in Michigan.

Other addiction medicine in Norton Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →